International law firm McDermott Will & Emery represented Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, in its $12 million public offering.

The offering is comprised of 9,230,769 Units with each Unit consisting of one share of common stock (or pre-funded warrant), one Series A Warrant to purchase one share of common stock exercisable on the date of stockholder approval and expiring  on the fifth anniversary thereof, and one Series B Warrant to purchase one share of common stock exercisable on the date of stockholder approval and expiring one year from the date thereof or, pursuant to an alternative cashless exercise option, the right to receive three shares of common stock.

The McDermott team was led by Merrill M. Kraines and Todd Kornfeld and included Brandon Sloane.

Read Applied DNA’s announcement.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

International law firm McDermott Will & Emery represented Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, in entering into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to an aggregate of 1,672,452 shares of common stock. The Series A and Series B warrants will be exercisable beginning on the effective date of stockholder approval and, in the case of Series A warrants, will expire one year from the date of stockholder approval, and in the case of Series B warrants, will expire five years from the date of stockholder approval.

The Company also entered into a warrant inducement agreement with the investor to exercise certain outstanding warrants. In consideration therefor, the Company agreed to reduce the exercise price of the unexercised portion of such warrants and to issue Series C warrants and Series D warrants exercisable beginning on the effective date of stockholder approval. The Series C warrants will expire one year from the date of stockholder approval and the Series D warrants will expire five years from the date of stockholder approval.

The McDermott team was led by Merrill Kraines, Todd Kornfeld, and Brian Tratner.

Read Inhibikase’s press release.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.